Issue link: https://www.e-digitaleditions.com/i/977310
6 May 2018 Tablets & Capsules ceutical subsidiary, Schaffhausen, Switzerland, to expand Probi's product development pipeline and commercialize its strain of probiotics. The companies will initiate a probiotic development program funded by Cilag and carried out by Probi. Saneca renews solid oral dosage agreement with Pharmascience HLOHOVEC, Slovakia—Saneca Pharma, a CDMO, has renewed its a g r e e m e n t w i t h P h a r m a s c i e n c e , Montreal, QC, to manufacture and supply its prescription solid dosage products. This includes 600 million enteric, chewable, and film-coated tablets per year and will involve R&D and lab analyses related to existing and emerging formulations, as well as technical support in delivery to the Canadian pharma- ceutical market. Noramco partners with AFC WILMINGTON, DE—Noramco, a supplier of controlled substances, and API manufacturer AMPAC Fine Chemicals (AFC), Rancho Cordova, CA, are partnering to produce certain US DEA- controlled substances used to treat add- iction, prevent abuse, create cannabinoids for clinical indications, and treat ADHD. Noramco will continue to market the products, and AFC will act as a contract manufacturer to supplement Noramco's existing manufacturing capacity. Briefly noted… Cipla, Mumbai, India, and Aurobindo Pharma, Hyderabad, India, won FDA approval for their generic versions of Amgen's Sensipar (cinacalcet hydroch- loride), a calcium reducer that treats thy- roid issues for certain patients on dialysis. The agency also approved Tasigna (nilotinib) to treat first- and second-line pediatric patients age one and older with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase (Ph+ CML-CP). The product is manufactured by Novartis, Basel, S w i t z e r l a n d , a n d w a s p r e v i o u s l y approved to treat adult and pediatric patients age one and older with newly diagnosed Ph+ CML-CP resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy, as well as adult patients with Ph+ CML in chronic phase and accelerated phase, resistant or intolerant to prior therapy that included imatinib.